Travere Therapeutics, Inc.
NASDAQ:TVTXBiotechnology
+$0.65 today
- Market cap
- $4.82B
- Beta
- 1.14
- P/E (TTM)
- -235.0
- EPS (TTM)
- -$0.23
Volume 0.84M
Average 2.31M
TVTX Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Travere Therapeutics, Inc.NASDAQ: TVTX
Net Margin · Q3 FY2026 · quarter ended Sep 2026
Net margin narrows to -23.3%
Net margin was -23.3% in Q3 FY2026, down 38.9 pp from a year earlier. On a trailing-twelve-month basis it was -18.7%, up 1.7 pp year over year. Over 3 fiscal years it widened by 249.2 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 11 analysts of -8.8% for the fiscal year ending Dec 2026, down from -5.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -23.3%-2.8 pp QoQ
- Last fiscal yearDec 2025
- -5.2%+132.7 pp YoY
- LTMSep 2026
- -18.7%+1.7 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -5.2%
- Year-over-year change
- +132.7pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -5.2% | +132.7pp |
| FY2024 | 2024-12-31 | -137.9% | -61.2pp |
| FY2023 | 2023-12-31 | -76.7% | +177.7pp |
| FY2022 | 2022-12-31 | -254.4% | -117.8pp |
| FY2021 | 2021-12-31 | -136.6% | — |
Net Margin vs competitors
How TVTX compares with its peers on the latest reported figures
- TVTX's LTM Sep 2026 net margin of -18.7% is the 2nd highest of the 4 companies compared; the peer median is -612.7%.
- Its year-over-year change of +1.7 pp is the 3rd highest of 4, against a peer median of +7.7 pp.
- Over three fiscal years its change of +249.2 pp compares with a peer median of -5.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 3.3% | +7.7 pp | -5.9 pp | |
| LTM Sep 2026 | -18.7% | +1.7 pp | +249.2 pp | |
| LTM Mar 2026 | -612.7% | -643.7 pp | — | |
| LTM Mar 2026 | -8418.0% | +13944.1 pp | — | |
| FY2025 | — | — | — | |
| Peer median (excluding TVTX) | -612.7% | +7.7 pp | -5.9 pp | |
Competitors are the stored peer set for TVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 131.84M | 109.46M | 145.24M | 233.18M | 490.73M |
| Cost of Revenue | 3.82M | 4.42M | 11.45M | 7.74M | 10.34M |
| Gross Profit | 128.02M | 105.04M | 133.79M | 225.43M | 480.39M |
| Gross Margin | 97.1% | 96.0% | 92.1% | 96.7% | 97.9% |
| Research & Development | 201.16M | 227.33M | 244.99M | 282.7M | 206.01M |
| Selling, General & Admin | 126.28M | 197.52M | 265.54M | 264.12M | 337.2M |
| Operating Expenses | 327.44M | 424.85M | 521.93M | 549.26M | 543.21M |
| Depreciation & Amortization | 12.75M | 20.72M | 38.53M | 43.56M | 60.74M |
| EBITDA | (184.46M) | (299.42M) | (326.25M) | (265.77M) | 22.22M |
| EBITDA Margin | -139.9% | -273.5% | -224.6% | -114.0% | 4.5% |
| Operating Income | (199.43M) | (319.81M) | (388.14M) | (323.83M) | (62.82M) |
| Operating Margin | -151.3% | -292.2% | -267.2% | -138.9% | -12.8% |
| Interest Income | 1.99M | 6.28M | 21.77M | 17.82M | 12.72M |
| Interest Expense | 19.68M | 11.01M | 11.33M | 11.18M | 10.75M |
| Other Income / Expenses | (17.46M) | (11.34M) | 12.03M | 3.32M | 13.55M |
| Income Before Tax | (216.88M) | (331.16M) | (376.11M) | (320.51M) | (49.27M) |
| Pre-Tax Margin | -164.5% | -302.5% | -259.0% | -137.5% | -10.0% |
| Income Tax Expense | 409K | 313K | 223K | 120K | 988K |
| Net Income | (180.09M) | (278.48M) | (111.4M) | (321.55M) | (25.55M) |
| Net Margin | -136.6% | -254.4% | -76.7% | -137.9% | -5.2% |
| EPS (Basic) | (3.01) | (4.37) | (1.50) | (4.08) | (0.56) |
| EPS (Diluted) | (3.01) | (4.37) | (1.50) | (4.08) | (0.56) |
| Weighted Avg Shares | 59.83M | 63.76M | 74.27M | 78.89M | 89.21M |
| Weighted Avg Shares (Diluted) | 59.83M | 63.76M | 74.27M | 78.89M | 89.21M |
Travere Therapeutics, Inc.
NASDAQ:TVTX
Intrinsic Alpha fair value
Locked
Current Price
$50.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.